PROG Share Price | Biora Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Biora Therapeutics, Inc.?

Market Cap: As of Jun 18, Biora Therapeutics, Inc. has a market capitalization of 0.75 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Biora Therapeutics, Inc. reported net sales of 0.89 million and a net profit of -35.58 million.Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of -101.42 million and total assets of 31.21 million.

Q: What does Biora Therapeutics, Inc. do?

Overview: Biora Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing molecular testing products and precision medicine within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Sep 2024) Most recent Net Profit: -22 Million (Quarterly Results - Sep 2024) Market-cap: USD 0.75 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.34 Return on Equity: 75.48% Price to Book: -0.01Contact Details: Address: 4330 La Jolla Village Dr Ste 200, SAN DIEGO CA: 92122 Tel: ['1 760 4941555', '1 619 2282886'] Fax: 1 248 8481623 Website: https://www.progenity.com/

Q: Who are in the management team of Biora Therapeutics, Inc.?

As of March 2022, the management team of Biora Therapeutics, Inc. includes Dr. Harry Stylli, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the board consists of several independent directors: Mr. Jeffrey Alter, Mr. John Bigalke, Mr. Jeffrey Ferrell, Dr. Brian Kotzin, and Dr. Samuel Nussbaum.

Q: Is Biora Therapeutics, Inc. overvalued or undervalued?

As of 15 August 2022, the valuation grade for Biora Therapeutics, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, as evidenced by its extreme EV to Sales ratio of 36.76 and negative metrics across key financial ratios, including a Price to Book Value of -0.01 and an EV to EBITDA of -0.61. In comparison to its peers, Biora's valuation metrics are starkly unfavorable; for instance, GeneDx Holdings Corp. has a P/E ratio of -63.58 and an EV to EBITDA of 166.66, while Personalis, Inc. shows a P/E of -6.55 and an EV to EBITDA of -6.66. The company's stock has underperformed significantly against the S&P 500, with a one-year return of -97.99% compared to the index's 10.26%. Overall, Biora Therapeutics, Inc. presents a concerning investment outlook based on its current financial ratios and peer comparisons.

Q: Is Biora Therapeutics, Inc. technically bullish or bearish?

As of 18 July 2025, the technical trend for Biora Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the weekly KST is bearish, suggesting weakness in the short term. The RSI shows no signal on the weekly timeframe but is bullish on the monthly, which adds some mixed signals. Overall, the indicators point to a mildly bearish stance.The company has experienced significant declines, with a year-to-date return of -100.0%, underperforming the S&P 500, which has returned 12.22% in the same period.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Sep 2024)

FII

0.24%

Held by 10 FIIs

DII

97.33%

Held by 3 DIIs

Promoter

0.00%

How big is Biora Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Biora Therapeutics, Inc. has a market capitalization of 0.75 million, with net sales of 0.89 million and a net profit of -35.58 million over the last four quarters. As of Dec 23, the company reported shareholder's funds of -101.42 million and total assets of 31.21 million.

View full answer

What does Biora Therapeutics, Inc. do?

22-Jun-2025

Biora Therapeutics, Inc. is a biotechnology company focused on developing molecular testing products and precision medicine. As of September 2024, it has a market cap of $0.75 million, with net sales of $0 million and a net loss of $22 million.

View full answer

Who are in the management team of Biora Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Biora Therapeutics, Inc.'s management team includes Dr. Harry Stylli as Chairman and CEO, along with independent directors Mr. Jeffrey Alter, Mr. John Bigalke, Mr. Jeffrey Ferrell, Dr. Brian Kotzin, and Dr. Samuel Nussbaum.

View full answer

Is Biora Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 15, 2022, Biora Therapeutics, Inc. is considered overvalued and has a concerning investment outlook due to its extreme EV to Sales ratio of 36.76, negative financial metrics, and significant underperformance compared to the S&P 500.

View full answer

Is Biora Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of July 18, 2025, Biora Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, including bearish daily moving averages and a year-to-date return of -100.0%, significantly underperforming the S&P 500's 12.22% return.

View full answer

Compare Biora Therapeutics, Inc. with Similar Stocks

Dyadic International, Inc.Sera Prognostics, Inc.Personalis, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.34

Return on Equity

75.48%

Price to Book

0.00

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2024)

Net Profit:

-22 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-100.0%

6 Months

-100.0%

1 Year

-100.0%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Biora Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-67.57%

EBIT Growth (5y)

13.92%

EBIT to Interest (avg)

-11.14

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.34

Sales to Capital Employed (avg)

0.00

Tax Ratio

2.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

38.05%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.01

EV to EBIT

-0.60

EV to EBITDA

-0.61

EV to Capital Employed

-0.52

EV to Sales

36.76

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (2.43%)

Foreign Institutions

Held by 10 Foreign Institutions (0.24%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -100.00% vs -40.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -441.54% vs 254.76% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.10",
          "val2": "-15.70",
          "chgp": "-2.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "0.70",
          "chgp": "185.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "8.30",
          "val2": "13.00",
          "chgp": "-36.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.20",
          "val2": "6.50",
          "chgp": "-441.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-507,093.80%",
          "val2": "-49,641.50%",
          "chgp": "-45,745.23%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -100.00% vs -75.00% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -154.71% vs 72.66% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-66.60",
          "val2": "-60.90",
          "chgp": "-9.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9.80",
          "val2": "11.00",
          "chgp": "-10.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "14.90",
          "val2": "20.90",
          "chgp": "-28.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-124.30",
          "val2": "-48.80",
          "chgp": "-154.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-16,785,750.00%",
          "val2": "-202,560.70%",
          "chgp": "-16,58,318.93%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ

Sep'24

Jun'24

Change(%)

Net Sales

0.00

0.30

-100.00%

Operating Profit (PBDIT) excl Other Income

-16.10

-15.70

-2.55%

Interest

2.00

0.70

185.71%

Exceptional Items

8.30

13.00

-36.15%

Consolidate Net Profit

-22.20

6.50

-441.54%

Operating Profit Margin (Excl OI)

-507,093.80%

-49,641.50%

-45,745.23%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2024 is -100.00% vs -40.00% in Jun 2024

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is -441.54% vs 254.76% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

0.00

0.30

-100.00%

Operating Profit (PBDIT) excl Other Income

-66.60

-60.90

-9.36%

Interest

9.80

11.00

-10.91%

Exceptional Items

14.90

20.90

-28.71%

Consolidate Net Profit

-124.30

-48.80

-154.71%

Operating Profit Margin (Excl OI)

-16,785,750.00%

-202,560.70%

-16,58,318.93%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is -100.00% vs -75.00% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -154.71% vs 72.66% in Dec 2022

All Annual Results

Company CV

About Biora Therapeutics, Inc.

Biora Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Progenity, Inc. is a biotechnology company. The Company is engaged in developing and commercializing molecular testing products and precision medicine. It applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. It offers integrated molecular tests and end-to-end support services that enable physicians to incorporate genetic testing into their office workflow and enables in ordering multiple tests from one source. The Company’s molecular tests are: Innatal Prenatal Screen, Preparent Carrier Test, Riscover Hereditary Cancer Test, Resura Prenatal Test for Monogenic Disease, and Anatomic and Molecular Pathology Tests. It is also developing an ingestible capsule platform designed to help diagnose and treat gastrointestinal (GI) disorders.

Company Coordinates

Company Details

4330 La Jolla Village Dr Ste 200 , SAN DIEGO CA : 92122

Tel: 1 760 49415551 619 2282886

https://www.progenity.com/

Registrar Details

Biora Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Biora Therapeutics, Inc.?

Watch in Real-Time

What does Biora Therapeutics, Inc. do?

Who are in the management team of Biora Therapeutics, Inc.?

Is Biora Therapeutics, Inc. overvalued or undervalued?

Is Biora Therapeutics, Inc. technically bullish or bearish?

Compare Biora Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ

Annual Results Snapshot (Consolidated) - Dec'23

About Biora Therapeutics, Inc.

Company Coordinates